Guardant Health (GH) announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. “2024 was an outstanding ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. For the three-month ...

Personalized medicine is revolutionizing lung cancer treatment by tailoring approaches to genetic profiles, leading to more ...

Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for ...

New research from the University of St Andrews School of Medicine has found that biomarker testing in individuals at risk of ...

OXcan was founded in 2020 by Dr. Peter Jianrui Liu and Dr. Andreas Halner to advance early cancer detection using liquid biopsy.

Medtech Oxford Cancer Analytics (OXcan) said it has raised US$11m in Series A funding from global investors, including ...

Bone marrow biopsy is a term used to describe a surgical procedure in which a small portion of bone marrow is extracted from ...

BALTIMORE and PALO ALTO, Calif., Jan. 8, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc. , developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer ...

A new blood test to detect cancer at an early stage has shown promising results, according to a study, as scientists aim to ...

The platform analyses gene expression and cell states specific to individual cells, offering insights for disease diagnosis.

The "Tumor Profiling Market by Technique, by Technology, by Application, by End-User, and By Region" report has been added to ...